From Wikipedia, the free encyclopedia


					Jump to:					navigation, 					search


Teniposide




Systematic (IUPAC) name



(5R,5aR,8aR,9S)-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-({4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl}oxy)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one



Clinical data


Trade names
Vumon


AHFS/Drugs.com
monograph


MedlinePlus
a692045


Pregnancy
category



AU: D
US: D (Evidence of risk)








Legal status



US: ℞-only





Routes of
administration
Intravenous


Pharmacokinetic data


Bioavailability
N/A


Protein binding
>99%


Metabolism
Hepatic (CYP2C19-mediated)


Biological half-life
5 hours


Excretion
Renal and fecal


Identifiers


CAS Number
29767-20-2 Y


ATC code
L01CB02


PubChem
CID 34698


IUPHAR/BPS
6843


DrugBank
DB00444 N


ChemSpider
31930 N


UNII
957E6438QA N


KEGG
D02698 Y


ChEBI
CHEBI:75988 N


ChEMBL
CHEMBL1200536 N


Synonyms
VM-26


Chemical data


Formula
C32H32O13S


Molar mass
656.655 g/mol




SMILES


COc1cc(cc(c1O)OC)[C@@H]2c3cc4c(cc3[C@H]([C@@H]5[C@@H]2C(=O)OC5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)c8cccs8)O)O)OCO4








InChI


InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31?,32-/m0/s1


Key:NRUKOCRGYNPUPR-PSZSYXFXSA-N






 NY (what is this?)  (verify)


Teniposide (trade name Vumon) is a chemotherapeutic medication[1] used in the treatment of childhood acute lymphocytic leukemia (ALL), Hodgkin's lymphoma, certain brain tumours, and other types of cancer.[2] It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.[3]



Contents


1 Medical uses

1.1 Administration


2 Contraindiactions
3 Side effects
4 Interactions
5 Pharmacology

5.1 Mechanism of action


6 Physical and chemical properties
7 References



Medical uses[edit]
Teniposide is used for the treatment of a number of cancer types in children. In the US, it is approved for the second-line therapy of acute lymphocytic leukemia (ALL) in combination with other antineoplastic drugs.[3] In Europe, it is also approved for the treatment of Hodgkin's lymphoma, generalized malignant lymphoma, reticulocyte sarcoma, acute leukaemia, primary brain tumours (glioblastoma, ependymoma, astrocytoma), bladder cancer, neuroblastoma and other solid tumours in children.[2]
Administration[edit]
The medication is injected though a vein and burns if it leaks under the skin. It can be used in combination with other anticancer drugs.[2]
Contraindiactions[edit]
The drug is contraindicated during pregnancy and lactation, in patients with severe liver or kidney impairment or severely impaired haematopoiesis.[2]
Side effects[edit]
Teniposide, when used with other chemotherapeutic agents for the treatment of ALL, results in severe bone marrow suppression. Other common side effects include gastrointestinal toxicity, hypersensitivity reactions, and reversible alopecia.[2]
Interactions[edit]
No systematic interaction studies are available. The enzyme inducers phenobarbital and phenytoin have been found to lower its blood plasma concentrations.[4] Theoretically possible interactions include increased plasma concentrations when combined with sodium salicylate, sulfamethizole or tolbutamide, which displace teniposide from plasma protein binding, at least in vitro.[2][3]
Pharmacology[edit]
Mechanism of action[edit]
Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA-protein cross-links.[2] The substance has been found to act as an inhibitor of topoisomerase II (an enzyme that aids in DNA unwinding),[4][5] since it does not intercalate into DNA or bind strongly to DNA. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.[citation needed]
Physical and chemical properties[edit]




An illustration of the wild mandrake, showing part of the rhizome (at bottom)


Teniposide is a semisynthetic derivative of podophyllotoxin[2] from the rhizome of the wild mandrake (Podophyllum peltatum). More specifically, it is a glycoside of podophyllotoxin with a D-glucose derivative. It is chemically similar to the anti-cancer drug etoposide, being distinguished only by a thienyl rest where etoposide has a methyl.[4] Both these compounds have been developed with the aim of creating less toxic derivatives of podophyllotoxin.[6]
References[edit]


^ Cragg, Gordon M.; Newman, David J. (2005). "Plants as a source of anti-cancer agents". Journal of Ethnopharmacology 100 (1–2): 72–9. doi:10.1016/j.jep.2005.05.011. PMID 16009521. 
^ a b c d e f g h Jasek, W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 8855–6. ISBN 978-3-85200-181-4. 
^ a b c Drugs.com: Teniposide monograph.
^ a b c Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 894–5. ISBN 3-8047-1763-2. 
^ De Jong, S; Kooistra, A. J.; De Vries, E. G.; Mulder, N. H.; Zijlstra, J. G. (1993). "Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells". Cancer research 53 (5): 1064–71. PMID 8382551. 
^ Dinnendahl, V, Fricke, U, ed. (2015). Arzneistoff-Profile (in German) 4 (28 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3. 










v
t
e


Intracellular chemotherapeutic agents / antineoplastic agents (L01)






SPs/MIs
(M phase)




Block microtubule assembly



Vinca alkaloids (Vinblastine#
Vincristine#
Vinflunine§
Vindesine
Vinorelbine)








Block microtubule disassembly



Taxanes (Cabazitaxel
Docetaxel#
Larotaxel
Ortataxel†
Paclitaxel#
Tesetaxel)
Epothilones (Ixabepilone)











DNA replication
inhibitor




DNA precursors/
antimetabolites
(S phase)




Folic acid



Dihydrofolate reductase inhibitor (Aminopterin
Methotrexate#
Pemetrexed
Pralatrexate)
Thymidylate synthase inhibitor (Raltitrexed
Pemetrexed)








Purine



Adenosine deaminase inhibitor (Pentostatin)


Halogenated/ribonucleotide reductase inhibitors (Cladribine
Clofarabine
Fludarabine)
Nelarabine


Thiopurine (Thioguanine#
Mercaptopurine#)








Pyrimidine



Thymidylate synthase inhibitor (Fluorouracil#
Capecitabine
Tegafur (+gimeracil/oteracil)
Carmofur
Floxuridine)


DNA polymerase inhibitor (Cytarabine#)


Ribonucleotide reductase inhibitor (Gemcitabine)


Hypomethylating agent (Azacitidine
Decitabine)








Deoxyribonucleotide



Ribonucleotide reductase inhibitor (Hydroxycarbamide)











Topoisomerase inhibitors
(S phase)




I



Camptotheca (Camptothecin
Topotecan
Irinotecan
Rubitecan‡
Belotecan)








II



Podophyllum (Etoposide#
Teniposide)








II+Intercalation



Anthracyclines (Aclarubicin
Daunorubicin#
Doxorubicin#
Epirubicin
Idarubicin
Amrubicin†
Pirarubicin
Valrubicin
Zorubicin)
Anthracenediones (Mitoxantrone
Pixantrone)











Crosslinking of DNA
(CCNS)




Alkylating



Nitrogen mustards: Mechlorethamine
Cyclophosphamide# (Ifosfamide
Trofosfamide)
Chlorambucil# (Melphalan
Prednimustine)
Bendamustine
Uramustine
Estramustine


Nitrosoureas: Carmustine
Lomustine (Semustine)
Fotemustine
Nimustine
Ranimustine
Streptozocin


Alkyl sulfonates: Busulfan (Mannosulfan
Treosulfan)


Aziridines: Carboquone
ThioTEPA
Triaziquone
Triethylenemelamine








Platinum-based



Carboplatin
Cisplatin
Nedaplatin
Oxaliplatin
Satraplatin








Nonclassical



Hydrazines (Procarbazine#)
Triazenes (Dacarbazine#
Temozolomide)
Altretamine
Mitobronitol
Pipobroman








Intercalation



Streptomyces (Actinomycin#
Bleomycin#
Mitomycin
Plicamycin)














Photosensitizers/PDT



Aminolevulinic acid / Methyl aminolevulinate
Efaproxiral
Porphyrin derivatives (Porfimer sodium
Talaporfin
Temoporfin
Verteporfin)








Other




Enzyme inhibitors



FI (Tipifarnib§)
CDK inhibitors (Alvocidib†
Seliciclib†
Palbociclib)
PrI

Bortezomib
Carfilzomib
Ixazomib


PhI (Anagrelide)
IMPDI (Tiazofurin§)
LI (Masoprocol)
PARP inhibitor (Olaparib)
HDAC (Belinostat
Panobinostat
Romidepsin
Vorinostat)
PIKI (Idelalisib)








Receptor antagonists



ERA (Atrasentan)
Retinoid X receptor (Bexarotene)
Sex steroid (Testolactone)








Other/ungrouped



Amsacrine
Trabectedin
Retinoids (Alitretinoin
Tretinoin)
Arsenic trioxide
Asparagine depleters (Asparaginase#/Pegaspargase)
Celecoxib
Demecolcine
Elesclomol§
Elsamitrucin
Etoglucid
Lonidamine
Lucanthone
Mitoguazone
Mitotane
Oblimersen†
Omacetaxine mepesuccinate
Eribulin















#WHO-EM
‡Withdrawn from market
Clinical trials:

†Phase III
§Never to phase III














 
						